^
    Back
    Association details:
    Biomarker:EPHB1 mutation
    Cancer:Colorectal Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    EPHB1 mutation predicts survival from treatment with immune checkpoint inhibitors and correlated with higher TMB and immune infiltrates in mCRC.

    Published date:
    05/26/2022
    Excerpt:
    7.3%(8/109) patients in the clinical cohort harbored EPHB1 mutation. Survival analysis in the public cohort demonstrated that EPHB1 mutation resulted in significantly longer OS (14 vs 8 months; HR, 0; p = 0.03) in mCRC patients treated with ICIs.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e15559